REGULATORY

Pipe Damage Causes Water Leak at Sawai Plant after Quake: MHLW

July 30, 2026
Japanese Health Minister Kenichiro Ueno
Japanese Health Minister Kenichiro Ueno

A water leak caused by damaged piping has been reported at one of Sawai Pharmaceutical's factories in Fukuoka Prefecture following a massive earthquake that hit southwestern Japan on July 28. However, the incident is unlikely to affect product supplies.

The Ministry of Health, Labor and Welfare (MHLW) said on July 29 that the leak at Sawai’s Daini Kyushu Factory is expected to take several days to repair, but the generic maker has sufficient inventory to maintain supplies. Other manufacturers have also reported damage, but none has reported disruptions to product supply.

At a meeting of the ministry’s disaster response headquarters the same day, Health Minister Kenichiro Ueno said three MHLW officials had been dispatched to the Kumamoto prefectural government to support disaster response efforts. He instructed ministry staff to continue gathering information and provide all possible assistance to affected residents.

Related Article

REGULATORY

By Kohei Hori

A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…

By Hayate Horiguchi

A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…

By Tatsuya Otsuka

On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…

By Hayate Horiguchi

Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…

By Shunsuke Tani

Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…